The therapeutic concepts for erectile dysfunction: the test of time
##plugins.themes.bootstrap3.article.sidebar##
##plugins.themes.bootstrap3.article.main##
Abstract
The article discusses the history and development of modern methods of treatment of erectile dysfunction: psychosexual correction, LNP-therapy, drug therapy, iPDE-5, intracovernosal therapy by alprostadil, surgical arterialization of the cavernous bodies of faloimitation. Based on the analysis of data regarding the efficacy, safety and relevance to patients and professionals of early refuse treatment, we can conclude that none of these methods meets the needs of the patient fully. Currently there is a great need for technology that will allow you to restore the structure and function of the cavernous tissue. This technology needs to solve such problem as providing the patient the most natural sexual activity as well as the problem associated with the lack of response to pharmacotherapy in irreversible damage to NO-producing structures. The results suggest that cellular and molecular techniques have optimistic future application in patients with erectile dysfunction.
##plugins.themes.bootstrap3.article.details##
This work is licensed under a Creative Commons Attribution 4.0 International License.
Authors retain the copyright and grant the journal the first publication of original scientific articles under the Creative Commons Attribution 4.0 International License, which allows others to distribute work with acknowledgment of authorship and first publication in this journal.
References
EAU guidelines for male-sexual-dysfunction 2016 // http://uroweb.org/guideline/male-sexual-dysfunction.
Historical highlights of erectile and sexual dysfunction an illustrated chronology // http://edlogs.blogspot.de/2007/08/historical-highlights-of-erectile-and_30.
Lewis R.W., Witherington R. External vacuum therapy for erectile dysfunction: use and results. World J Urol. 1997;15(1):78–82.
Levine L.A., Dimitriou R.J. Vacuum constriction and external erection devices in erectile dysfunction // Urol Clin North Am. 2001 May; 28(2):335–41.
Vrijhof H.J., Delaere K.P. Vacuum constriction devices in erectile dysfunction: acceptance and effectiveness in patients with impotence of organic or mixed aetiology //Br J Urol. 1994 Jul;74(1):102–5.
Gilbert H.W., Gingell JC. Vacuum constriction devices: second-line conservative treatment for impotence //Br J Urol. 1992 Jul; 70(1):81–3.
Hartmann U. Sigmund Freud and his impact on our understanding of male sexual dysfunction //J Sex Med. 2009 Aug;6(8):2332–9.
Katzenstein A., Thom A. The historical achievement and the limits of the work of Sigmund Freud (1855–1939) //Psychiatr Neurol Med Psychol (Leipz). 1982 Feb;34(2):68–78.
Silverstein B. Freud’s psychology and its organic foundation: sexuality and mind-body interactionism // Psychoanal Rev. 1985; 72(2):203–28.
Мастерc У., Джонсон В., Колодни Р. Основы сексологии. – М.: Мир, 1998. – 692 с.
Molodysky E., Liu S.P., Huang S.J., Hsu G.L. Penile vascular surgery for treating erectile dysfunction: Current role and future direction // Arab J Urol. 2013; 11(3):254–66.
Martínez Portillo F.J., Jünemann K.P., Sohn M. Surgical therapy of erectile dysfunction. Current status // Urologe A. 2003 Oct; 42(10):1337–44.
Sexton W.J., Benedict J.F., Jarow J.P. Comparison of long-term outcomes of penile prostheses and intracavernosal injection therapy // J Urol. 1998 Mar;159(3):811–5.
Segal R.L., Bivalacqua T.J., Burnett A.L. Current penile-rehabilitation strategies: Clinical evidence. //Arab J Urol. 2013 Sep;11(3):230–6.
Polito M., d’Anzeo G., Conti A., Muzzonigro G. Erectile rehabilitation with intracavernous alprostadil after radical prostatectomy: refusal and dropout rates. BJU Int. 2012 Dec;110(11 Pt C):E954–7.
Kimura M1, Caso JR, Baсez LL, Koontz BF, Gerber L, Senocak C, Donatucci CF, Vujaskovic Z, Moul JW, Polascik TJ. Predicting participation in and successful outcome of a penile rehabilitation programme using a phosphodiesterase type 5 inhibitor with a vacuum erection device after radical prostatectomy. BJU Int. 2012 Dec;110(11 Pt C):E931–8.
Ravipati G., McClung J.A., Aronow W.S., Peterson S.J., Frishman W.H. Type 5 phosphodiesterase inhibitors in the treatment of erectile dysfunction and cardiovascular disease. Cardiol Rev. 2007 MarApr;15(2):76–86.
Smith-Harrison L.I., Patel A., Smith R.P. The devil is in the details: an analysis of the subtleties between phosphodiesterase inhibitors for erectile dysfunction // Transl Androl Urol. 2016
Apr;5(2):181–6.
Elhwuegi A.S. The Wonders of Phosphodiesterase-5 Inhibitors: A Majestic History. Ann Med Health Sci Res. 2016 May-Jun;6(3):139–45.
Shindel AW 2009 update on phosphodiesterase type 5 inhibitor therapy part 1: Recent studies on routine dosing for penile rehabilitation, lower urinary tract symptoms, and other indications (CME). J Sex Med. 2009 Jul; 6(7): 1794–808.
Shindel A.W. 2009 update on phosphodiesterase type 5 inhibitor therapy part 2: updates on optimal utilization for sexual concerns and rare toxicities in this class //J Sex Med. 2009
Sep;6(9):2352–64.
Jannini E.A., Isidori A.M., Gravina G.L., Aversa A., Balercia G., Bocchio M., Boscaro M., Carani C., Corona G., Fabbri A., Foresta C., Forti G., Francavilla S., Granata A.R., Maggi M., Mansani R., Palego P., Spera G., Vetri M., Lenzi A.; Endotrial Study Group. The ENDOTRIAL study: a spontaneous, open-label, randomized, multicenter, crossover study on the efficacy of sildenafil, tadalafil, and vardenafil in the treatment of erectile dysfunction. J Sex Med. 2009 Sep; 6(9): 2547–60.
Lipsker A, Saljoghi R, Lecuelle D, Caillet K, Alezra E, Le Roux F, Demailly M, Saint F. Evolution of the number and type of penile prostheses implanted in France for erectile dysfunction: Analysis of French national coding database (2006-2013) //Prog Urol. 2016 Aug 30. pii: S1166-7087(16)30400–6.
Горпинченко И., Гурженко Ю., Имшинецкая Л., Корниенко А., Недогонова Е., Нуриманов К., Романюк М., Романенко О., Соколова М., Сытенко А. – К.: Профессионал, 2008. – 191 с.
Lin C.S., Xin Z., Dai J., Huang Y.C., Lue T.F. Stem-cell therapy for erectile dysfunction //Expert Opin Biol Ther. 2013 Nov;13(11):1585–97.
Горпинченко І.І. Вплив інтракавернозних ін’єкцій кістковомозкових мезенхімальних стовбурових клітин на морфологію та фосфатазну активність печеристої тканини щурів-самців із стрептозотоцин-індукованим цукровим діабетом / І.І. Горпинченко, А.М. Ситенко, Т.А. Бухтіарова, О.Є. Ядловський, А.В. Матвієнко, А.Г. Попандопуло, А.С. Кавеліна // Здоровье мужчины. – 2013. – No 4. – С. 142–145.
